Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis
Nanako Hamada, Yoshiaki Hayashi, Daisuke Motooka, Atsushi Kuwahara, Shizuo Akira, Kiyoharu Fukushima · 2026
Read Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis by Nanako Hamada, Yoshiaki Hayashi, Daisuke Motooka, Atsushi Kuwahara, Shizuo Akira, Kiyoharu Fukushima (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13633504.txt.
Description
Nanako Hamada and five colleagues studied how an approved lung fibrosis drug works at the level of single cells. The drug, nerandomilast, slows a disease where lung tissue scars and stiffens until breathing fails. Trials proved it helps patients, yet its cellular actions stayed unclear. The team gave the drug to mice with chemically induced lung scarring. They then read gene activity cell by cell in the injured lungs.
Treated mice showed less fibrotic remodeling and better preserved air sac walls. The drug shifted the behavior of type 2 alveolar cells, the surface cells that repair air sacs and make the coating that keeps them open. Those cells became more numerous and more active in cell-division programs. Staining confirmed a larger area covered by their marker protein. The findings suggest the drug protects the lung partly by supporting these repair cells.
Catalog record
| CREATOR | Nanako Hamada, Yoshiaki Hayashi, Daisuke Motooka, Atsushi Kuwahara, Shizuo Akira, Kiyoharu Fukushima |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |